Related Experiment Video
Updated: Jul 11, 2025
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis.
Shirley O'Leary1,2,3,4,5,6,7,8,9,10,11, Helen T Brugger1,2,3,4,5,6,7,8,9,10,11, Dale Wallentine1,2,3,4,5,6,7,8,9,10,11
1Dallas VA Medical Center MS Center, Dallas, Texas (Ms O'Leary); Long Ridge Medical Center, Neurology, Greenwich Hospital, Stamford, Connecticut (Ms Brugger); Rocky Mountain MS Clinic, Salt Lake City, Utah (Mr Wallentine); The Regional MS Center & The Center for Neurological Disorders, Milwaukee, Wisconsin (Ms Sershon); University of Alabama at Birmingham, Birmingham, Alabama (Ms Goff); Biogen, Cambridge, Massachusetts (Mss Saldana-King and Beavin; Drs Avila and Rutledge); Novant MS Care Center, Charlotte, North Carolina (Ms Moore).
Natalizumab, a monoclonal antibody DMT, is effective for relapsing multiple sclerosis (MS). This review synthesizes 16 years of real-world data on its long-term effectiveness, safety, and patient care strategies.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Natalizumab (TYSABRI®) is a high-efficacy monoclonal antibody therapy.
- It was the first DMT approved as monotherapy for relapsing multiple sclerosis (MS).
- Infusion nurses are crucial for patient care due to intravenous administration.
Purpose of the Study:
- To provide a synopsis of long-term, real-world effectiveness and safety data for natalizumab.
- To offer practical guidance for optimizing patient care.
- To update information on managing risks and specific patient populations.
Main Methods:
- Review of substantial data gathered over 16 years post-approval.
- Synopsis of real-world effectiveness and safety information.
- Compilation of practical care strategies.
Main Results:
- Natalizumab demonstrates long-term effectiveness and safety in real-world MS treatment.
- Key considerations include managing progressive multifocal leukoencephalopathy (PML) risk.
- Guidance is provided for use during pregnancy and with vaccines.
Conclusions:
- Natalizumab remains a vital treatment option for relapsing MS.
- Optimized patient care involves vigilant monitoring and risk mitigation strategies.
- This review offers essential information for healthcare providers managing natalizumab therapy.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:22Myocarditis IV: Nursing Management